Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
PYXS Pyxis Oncology
1.590-0.010-0.63%
Close
01/27 16:00 ET
1.5900.0000.00%
Post Mkt Price 01/27 16:00 ET
High
1.650
Open
1.610
Turnover
16.69K
Low
1.590
Pre Close
1.600
Volume
10.32K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Pyxis Oncology (NASDAQ:PYXS) Given Outperform Rating at Lifesci Capital
Lifesci Capital restated their outperform rating on shares of Pyxis Oncology (NASDAQ:PYXS – Get Rating) in a research note released on Thursday morning, PriceTargets.com reports. Pyxis Oncology Stoc
Pyxis Oncology Receives US FDA Clearance for Two Investigational New Drug Applications for Solid Tumor Treatments
07:22 AM EST, 12/01/2022 (MT Newswires) -- Pyxis Oncology (PYXS) said Thursday it has obtained clearance from the US Food and Drug Administration to start phase one clinical trials for two Investigati
Pyxis Oncology Announces FDA Clearance Of Two IND Applications
FDA grants IND clearances of PYX-201, a novel antibody-drug conjugate (ADC) product candidate, and PYX-106, an immunotherapy product candidatePhase 1 clinical trials of PYX-201 and PYX-106 will evalua
Pyxis Oncology, Inc. (NASDAQ:PYXS) Short Interest Up 286.1% in November
Pyxis Oncology, Inc. (NASDAQ:PYXS – Get Rating) saw a large growth in short interest during the month of November. As of November 15th, there was short interest totalling 160,600 shares, a growth of
12 Health Care Stocks Moving In Monday's After-Market Session
GainersKala Pharmaceuticals (NASDAQ:KALA) stock rose 24.8% to $7.09 during Monday's after-market session. This security traded at a volume of 108.5K shares come close, making up 65.4% of its average v
A Pyxis Oncology, Inc. (NASDAQ:PYXS) Insider Increased Their Holdings Last Year
Stocks That Hit 52-Week Lows On Friday
On Friday, 63 stocks hit new 52-week lows. Interesting Points From Today's 52-Week Lows: Algonquin Power (NYSE:AQN) was the biggest company in terms of market cap to set a new 52-week low.The smalle
Tang Capital Partners Buys PYXS / Pyxis Oncology After Q3 Results Reported
Lifesci Capital Equities Analysts Decrease Earnings Estimates for Pyxis Oncology, Inc. (NASDAQ:PYXS)
Pyxis Oncology, Inc. (NASDAQ:PYXS – Get Rating) – Equities researchers at Lifesci Capital cut their FY2022 earnings per share (EPS) estimates for shares of Pyxis Oncology in a research note issued
Analysts Offer Predictions for Pyxis Oncology, Inc.'s FY2022 Earnings (NASDAQ:PYXS)
Pyxis Oncology, Inc. (NASDAQ:PYXS – Get Rating) – Research analysts at William Blair raised their FY2022 EPS estimates for shares of Pyxis Oncology in a research note issued to investors on Tuesda
Company Overview
More
Pyxis Oncology, Inc. engages in the development of antibody therapeutics. The company was founded by David Steinberg, Shaan Gandhi, and John Flavin on June 11, 2018 and is headquartered in Cambridge, MA.
CEO： Dr. Lara S. Sullivan, M.D.
Market： NASDAQ
Listing Date： 10/08/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet